Antibody-Mediated Rejection Market Size to Reach US$ 401.8 Million by 2034, Impelled by Advancements in Early Detection

December 03, 2024 | Healthcare

VIEW FULL TABLE OF CONTENTS

Antibody-Mediated Rejection Market Outlook 2024-2034:

The antibody-mediated rejection market size reached a value of US$ 112.3 Million in 2023. Looking forward, the market is expected to reach US$ 401.8 Million by 2034, exhibiting a growth rate (CAGR) of 12.29% during 2024-2034. The market is driven by the emerging application of intravenous immunoglobulin therapy, which helps to eliminate dangerous antibodies from the recipient's bloodstream and modulates the immune response, thereby enhancing transplant survival rates. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Antibody-Mediated Rejection Market

To get more information on this market, Request Sample

Advances in Early Detection and Diagnostic Technologies: Driving the Antibody-Mediated Rejection Market

Advances in early detection and diagnostic technologies are playing a crucial role in driving the antibody-mediated rejection market and improving the management and outcomes of transplant patients. One of the major technological advancements in the early detection of antibody-mediated rejection is donor-specific antibody (DSA) testing. These blood tests identify the presence of antibodies directed against specific antigens on the donor organ, helping clinicians assess the risk of the disease. High-throughput screening methods, such as solid-phase assays and flow cytometry, have improved the sensitivity and specificity of DSA testing, enabling more accurate and earlier detection of antibody-mediated rejection, even before clinical symptoms appear. Furthermore, next-generation sequencing (NGS) is another cutting-edge diagnostic tool that is revolutionizing antibody-mediated rejection diagnosis. NGS allows for detailed genetic analysis of both donor and recipient tissues, identifying genetic mismatches that may increase the risk of the underlying condition. Moreover, biomarker discovery is opening new avenues for non-invasive monitoring of antibody-mediated rejection. Additionally, researchers are identifying molecular signatures associated with antibody-mediated rejection, which could lead to the development of blood-based biomarkers that allow for real-time monitoring of organ rejection, reducing the need for invasive biopsy procedures. This, in turn, is expected to drive the growth of the antibody-mediated rejection market.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is playing a pivotal role in the expansion of the antibody-mediated rejection market. Recent advances in biotechnology have led to the development of targeted therapies aimed at preventing the formation of antibodies or mitigating their harmful effects. Monoclonal antibodies, such as rituximab, eculizumab, and belatacept, have shown promise in selectively targeting the immune cells responsible for antibody production or directly inhibiting complement activation, a key mechanism in antibody-mediated rejection. These therapies are designed to reduce the risk of acute rejection and improve long-term graft survival, which has contributed to a significant shift in transplantation outcomes. Additionally, pharmacological innovations, including immune checkpoint inhibitors, complement inhibitors, and small molecule drugs, are opening new avenues for treating antibody-mediated rejection. These therapies aim to modulate the immune response more precisely, minimizing the systemic side effects seen with traditional immunosuppressive agents. The emergence of personalized medicine, where treatments are tailored to the genetic and immune profiles of individual patients, is further enhancing the effectiveness of antibody-mediated rejection management. As these novel therapies progress through clinical trials and gain regulatory approval, they are expected to significantly expand the antibody-mediated rejection treatment landscape. The growing focus on precision medicine, along with the increasing number of organ transplants globally, will likely continue to drive demand for innovative therapies in the antibody-mediated rejection market, ultimately improving transplant outcomes and patient quality of life.

Regional Analysis:

The major markets for antibody-mediated rejection include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for antibody-mediated rejection while also representing the biggest market for its treatment. This can be attributed to the rising utilization of organ transplant procedures, particularly kidney, heart, and lung transplants, which can increase the graft's production of antibodies specific for foreign antigens.

Moreover, advancements in immunology and biotechnology are another key driver. Significant progress in understanding the immune mechanisms behind antibody-mediated rejection has paved the way for novel therapies such as monoclonal antibodies, complement inhibitors, and immune-modulating drugs. These targeted treatments offer the potential to reduce the risks associated with traditional immunosuppressive therapies.

Besides this, the U.S. healthcare system's focus on precision medicine is contributing to market growth. Personalized treatments based on genetic and immunological profiles allow for more effective antibody-mediated rejection management, improving patient outcomes.

Key information covered in the report.

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the antibody-mediated rejection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the antibody-mediated rejection market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current antibody-mediated rejection marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Antibody-Mediated Rejection Market Size to Reach US$ 401.8 Million by 2034, Impelled by Advancements in Early Detection

Purchase Options New Year Sale

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.